ArticleScientific reports2026
Influences of formulations and administration routes on docetaxel tissue distribution in mice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Docetaxel (DTX) is an antimicrotubular chemotherapy drug widely used for treating various cancers. The objective of this study was to evaluate the impact of formulations and administration routes on DTX tissue distribution. The pharmacokinetics and tissue distribution of DTX were assessed using intravenous (IV) injection, intraperitoneal (IP) injection, oral solution, and oral granules in male CD-1 mice. Despite containing DTX crystals, oral DTX granules achieved tissue exposure comparable to that of the oral DTX solution, effectively addressing the poor solubility challenge of DTX while highlighting the need for strategies to enhance permeability in oral DTX formulations. Tissue distribution analysis revealed rapid elimination of DTX from the bloodstream and rapid uptake of DTX into tissue, regardless of formulation or route, emphasizing the importance of tissue concentrations over blood concentrations in evaluating therapeutic efficacy and toxicity for DTX. Notably, DTX exhibited lung selectivity, with oral formulations showing greater lung targeting compared to IP injection. These findings deepen the understanding of DTX tissue distribution and provide critical insights for DTX-based chemotherapy, as well as the development and optimization of novel DTX formulations, particularly for advancing oral DTX treatments and improving cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.